Acute Coronary Syndrome, Myocardial Infarction
Conditions
Keywords
ST elevated myocardial infarction, Acute coronary syndrome, MRX 801, Echocardiography
Brief summary
The study will see if mechanical impulses delivered by an echocardiographic probe during a continuous infusion of MRX 801 are capable of improving blood flow in smaller heart vessels in patients with acute coronary syndromes.
Detailed description
Pre-clinical studies have indicated that, during a continuous infusion of intravenous perfluorocarbon-containing microbubbles, the ultrasonic power delivered from a diagnostic ultrasound transducer is capable of restoring microcirculatory flow and improving epicardial recanalization rates following acute coronary thrombotic occlusions. Since both diagnostic ultrasound and intravenous infusions of microbubbles are a Class I indication to assess regional and global left ventricular function and risk area in patients with ST segment elevation myocardial infarction (STEMI), this pilot study will examine whether diagnostic assessments of left ventricular function and risk area size impacts epicardial recanalization rates and infarct size in STEMI. The aim of this study is to test whether guided high mechanical index impulses from a diagnostic transducer during a continuous infusion of intravenous microbubbles are capable of improving microvascular recanalization and epicardial recanalization rates in STEMI, as assessed by coronary angiography, and recovery of regional microvascular perfusion and function in the post-infarction period.
Interventions
DEVICEUse of intermittent high MI impulses during echocardiogram
Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
Sponsors
Microvascular Therapeutics, LLC
The Ruth and Bruce Rappaport Faculty of Medicine
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
InCor Heart Institute
Bnai Zion Medical Center
University of Nebraska
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, age ≥ 30 years. 2. Chest Pain occurring lasting less than six hours from onset, and EKG evidence of an acute ST segment elevation myocardial infarction. 3. Arrival in the Emergency Department with above inclusion criteria between 7 am and 7pm.
Exclusion criteria
1. Known or suspected hypersensitivity to ultrasound contrast agent used for the study. 2. Complicated hemodynamic instability (i.e., NYHA Class IV heart failure, unstable angina at rest despite medical therapy). 3. Life expectancy of less than two months or terminally ill. 4. Heart transplant recipient, hypertrophic cardiomyopathy, severe valvular disease, acute myo- or pericarditis. 5. Contraindication to Heart Catheterization 6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors or aspirin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improved microvascular recanalization and epicardial recanalization rates in STEMI as assessed by coronary angiography and recovery of regional microvascular perfusion and function in the post-infarction period. | 6 weeks | Improved microvascular recanalization and epicardial recanalization rates in STEMI as assessed by coronary angiography and recovery of regional microvascular perfusion and function in the post-infarction period. |
Outcome results
None listed